About Biovalence Technologies
-
May 26, 2020
2011
Founding of company, Biovalence Sdn Bhd
-
May 26, 2020
2013
US patent granted for “Antimicrobial Fusion Compound And Uses Thereof” by Abu Bakar Awang et al. US Patent Publication No. 2013/0336955 A1.
-
May 26, 2020
2014
Publication of Discovery Paper in PLOS ONE demonstrating the proof of concept of Biovalence Technologies recombinant proteomics technology against all 4 serotypes of the Dengue virus (Flaviviridae)
-
May 26, 2020
2014
Finalist at BioPharma 2014 showcasing the broad-spectrum antiviral activity of the world’s first genetically-designed antiviral proteins
-
May 26, 2020
2016
One of 4 recipients awarded for the Dengue Tech Challenge 2016 by the University of Cambridge, UK: https://www.britishcouncil.my/programmes/newton-ungku-omar-fund/dengue-tech-challenge-2016
-
May 26, 2020
Apr 2017
Finalist at BioPharma 2017 showcasing the pre-clinical studies of RetroMAD1, one of the 4 genetically-designed antiviral proteins
-
May 26, 2020
Aug 2017
Acquired by Singaporean angel investors and establishment of a Corporate HQs, Biovalence Technologies Pte Ltd, in Singapore for the purpose of attracting investors and commercialisation of RetroMAD1
-
May 26, 2020
Dec 2019
Publication of landmark field trial on RetroMAD1 in the treatment of feline leukaemia (Retroviridae) by the Federal University of Rio de Janeiro, Brazil
-
May 26, 2020
Mar 2020
The company is in the news with its commentary on the possible application of RetroMAD1 for Covid-19: https://www.scmp.com/news/asia/southeast-asia/article/3075604/coronavirus-singapore-start-thinks-cat-leukaemia-drug
-
May 26, 2020
Apr 2020
Pre-series A investment valuing the company at US$ 20 million
-
May 26, 2020
Apr 2020
Launch of e-commerce website, www.retromad1.com, for the US$16 billion pet therapeutics market
Management Team
Cher Yew NG
Chairman and
Chief Executive Officer
Dr. Cher Yew NG graduated from Murdoch University, Australia, in 1985 on a Colombo Plan Scholarship by the Singapore government. Cher Yew served at the Agri-foods and Veterinary Authority until 1991 as Deputy Director, Corporate Affairs. He then spent 14 years in China, actively involved in Life Science-related businesses as a distributor for MNCs like Solvay, IDEXX, Virbac, and Lohmann. He then served as Chairman and CEO of Oceanus Group Ltd, a Singapore-listed company until 2015. A co-founder of a fund manager, Springboard-Harper Investment Pte Ltd, he is also Chairman and CEO, having successfully managed a US$70 million fund. He took control of the Biovalence group of companies in 2017 and is now the incumbent Chairman and CEO of the group.
Awang MUHAMMAD
Chief Scientific Officer and
Chief Quality Assurance
Awang Muhammad Sagaf ABU BAKAR holds an MSc in Biotechnology from Universiti Malaysia Sabah (Malaysia). He specializes in molecular biology and protein engineering. He was Chief Biotechnologist while serving at Biosatria and Defensia. He has been involved in developing nucleic acid purification and extraction technology to allow in-house assimilation with diagnostics methods for the detection of pathogens in aquaculture. He is the original founder and main inventor of RetroMAD1 and his passion is to create products that would revolutionize the perception of treatment in human and animal diseases.
Alfred CHUA
Chief Marketing Officer and
Chief Veterinary Officer
Dr. Alfred CHUA graduated from the Ecole Nationale Vétérinaire de Lyon, France, in 1989 on a Colombo Plan Scholarship by the Singapore government. He served at the Agri-foods and Veterinary Authority until 1994 as Head of the Abattoir Inspection Unit and Head of the Microbiology and Drug Residue Unit. He then spent the next 19 years in corporate MNCs, heading the technical-marketing and regulatory units for Asia Pacific of Merial and Virbac. His last position was Marketing Director (Asia Pacific) of Kemin, a U.S.-based US$ 1 billion livestock feed additive company. In corporate, Alfred was involved in many M&A as the industry consolidated. Between 1999 and 2002, Alfred managed a China-based animal health distribution business. Alfred is now the Chief Marketing Officer of Biovalence.
Ashley SIM
Chief Financial Officer and
Chief Information Officer
Mr Ashley SIM CPA, graduated from the Nanyang Technological University on a Public Service Commission scholarship in 1993. He became CFO after the change in ownership of Biovalence in 2017. He has been the CFO of fund manager Springboard-Harper Investment Pte Ltd since 2012. Prior to that, he worked at the Ministry of Finance, ExxonMobil, and other MNCs. Other than finance, Ashley now oversees the human resource, legal, IT, and administrative functions of Biovalence.